Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

29.29 +0.27 (+0.93%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Beam Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026
Beam to Host Investor Webcast to Review BEAM-302 Clinical Data on Tuesday, September 8, 2026, at 7:00 a.m. ET 
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
Presentation Features Additional Data from the Single-dose Cohorts of the Phase 1/2 Trial, Including Detailed Safety Results, Efficacy Durability and Reduction in Human Neutrophil Elastase Activity... 
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
From Beam Therapeutics
Via GlobeNewswire
BioMedNewsBreaks — Beam Therapeutics Inc. (NASDAQ: BEAM) to Present New Sickle Cell Data from BEACON Trial at EHA2025
Via Investor Brand Network
News headline image
Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
From Beam Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.